BusinessworldBusinessworld

Max Healthcare, Fortis Lead Hospital Stock Recovery After Regulatory Concerns

閱讀1分鐘

Shares of leading hospital operators staged a strong recovery on Monday, with Max Healthcare, Fortis Healthcare, Aster DM Healthcare and Apollo Hospitals rising between 2 per cent and 6 per cent as investors returned to the sector following a recent correction triggered by regulatory concerns.

Max Healthcare led the rally, gaining 6.6 per cent to Rs 1,009. Fortis Healthcare advanced 5.13 per cent to Rs 803, while Aster DM Healthcare climbed 3.81 per cent to Rs 750. Apollo Hospitals closed 2.87 per cent higher at Rs 8,771.

The rebound follows a period of selling pressure in hospital stocks amid concerns that tighter government oversight of healthcare pricing could affect the profitability of private hospital chains. However, some market participants view the correction as an opportunity to accumulate shares, citing the sector’s long-term growth prospects.

India’s shortage of hospital beds, rising demand for healthcare services and the need for additional medical infrastructure continue to underpin the industry’s expansion outlook. Investors betting on the sector’s long-term prospects believe these structural factors could outweigh near-term regulatory uncertainties.

Pricing Concerns Trigger Regulatory Overhang

The recent weakness in hospital stocks followed renewed scrutiny of healthcare pricing practices. In September, the Supreme Court questioned the Centre on the possibility of introducing a uniform 16 per cent markup across medicines.

The court also raised concerns about pricing practices at corporate hospitals, particularly arrangements requiring patients to purchase medicines through in-house pharmacies or specified chemists.

These developments have raised questions about the extent of potential regulatory intervention and its implications for hospital revenues, margins and operating models.

While the latest recovery suggests some investors are looking beyond the immediate regulatory concerns, the sector’s performance is likely to remain sensitive to further developments on healthcare pricing and any measures proposed by the government.

For hospital operators, the central investment debate remains whether India’s structural shortage of healthcare infrastructure and rising demand can sustain earnings growth despite the possibility of tighter pricing regulation.

閱讀全文
無限制訪問Businessworld以及TradingView所有其他新聞來源的文章。